Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV-Reference-Cited by-同舟云学术

Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV

Published:2024-06-27 Issue:9 Volume:38 Page:1439-1442
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Johnson Arthur T.¹²,Ntloedibe Taolo³,Mendez Reyes Jose Euberto⁴,Matshaba Mogomotsi S.¹,Dryden-Peterson Scott L.³⁵⁶⁷,Chiao Elizabeth Y.⁸⁹

Affiliation:

1. Botswana Baylor Children's Clinical Center of Excellence

2. Department of Surgery, Princess Marina Hospital

3. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana

4. Department of Surgery, Baylor College of Medicine, Houston, Texas

5. Division of Cancer Prevention and Population Sciences, Department of Epidemiology, Harvard Medical School

6. Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital

7. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts

8. University of Texas MD Anderson Cancer Center

9. Division of Cancer Medicine University of Texas MD Anderson Cancer Center, Department of General Oncology, Houston, Texas, USA.

Abstract

Women living with HIV and breast cancer have poorer survival than HIV-negative women. Efavirenz–estrogen interactions are documented; however, the survival impact is unknown. Survival between women with estrogen-receptor positive breast cancer taking efavirenz (n = 38) and nonefavirenz regimens (n = 51) were compared. The 5-year overall-survival was 48.9% [95% confidence interval (CI) 33.0–72.2 and 51.1% (95% CI 34.0–76.8)] in the efavirenz and nonefavirenz groups, respectively suggesting efavirenz is unlikely driving poorer survival in women living with HIV and estrogen-receptor positive breast cancer.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference12 articles.

1. Impact of HIV infection on survival among women with stage I-III breast cancer: results from the South African breast cancer and HIV outcomes study;Ayeni;Int J Cancer,2022

2. Disparities in breast cancer survival between women with and without HIV across sub-Saharan Africa (ABC-DO): a prospective, cohort study;Chasimpha;Lancet HIV,2022

3. The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: lessons from Botswana;Maseng;Medicine (Baltimore),2022

4. The effect of efavirenz on estradiol metabolism in transgender women;Leinung;Transgend Health,2019

5. Breast abnormalities in adolescents receiving antiretroviral therapy;Dunlop;South Afr J HIV Med,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospects for breast cancer immunotherapy using microRNAs and transposable elements as objects;Exploration of Targeted Anti-tumor Therapy;2024-08-06